KalVista Pharmaceuticals Announces Board and Compensation Changes
Ticker: KALV · Form: 8-K · Filed: May 12, 2025 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: KALV
TL;DR
KalVista Pharma (KALV) filed an 8-K for board/exec comp changes. Details TBD.
AI Summary
On May 12, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific details on dollar amounts or new appointments are not yet elaborated in this initial report.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategic direction or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- May 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36830 (filing_id) — SEC File Number
- 20-0915291 (tax_id) — IRS Employer Identification No.
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but the specific names and roles of newly elected or departing directors are not detailed in this initial 8-K filing.
Are there any details on the new compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but specific details regarding these arrangements, including any dollar amounts or changes, are not provided in this report.
When was this report filed?
This report was filed on May 12, 2025.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SEC file number for KalVista Pharmaceuticals?
The SEC file number for KalVista Pharmaceuticals is 001-36830.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding KalVista Pharmaceuticals, Inc. (KALV).